Clinical Trial

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate: * What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan? * What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan? * What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-07-02
notable Enrollment reduced: 30 -> 1 participants 2026-07-02
notable Trial sites expanded: 1 -> 4 locations 2026-05-07
Trial Details
NCT Number NCT07391761
Lead Sponsor Pfizer
Conditions Refractory Multiple Myeloma (RRMM)
Enrollment 1 participants
Start Date 2026-05-11
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01